Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evalua...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical infectious diseases
Hauptverfasser:	Goswami, Jaya, Cardona, Jose F, Caso, Jorge, Hsu, Denise C, Simorellis, Alana K, Wilson, Lauren, Dhar, Rakesh, Wang, Xiaowei, Kapoor, Archana, Collins, Avi, Righi, Vinicius, Lan, Lan, Du, Jiejun, Zhou, Honghong, Stoszek, Sonia K, Shaw, Christine A, Reuter, Caroline, Wilson, Eleanor, Das, Rituparna
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 23.09.2025
Schlagworte:	mRNA RSV vaccine revaccination respiratory syncytial virus safety immunogenicity
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!